Antiparasitic Drugs Market - By Drug Type (Anthelmintics, Antiprotozoal, Ectoparasiticide), Route of Administration (Injectable, Oral, Topical), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 – 2032)

Antiparasitic Drugs Market Size

Antiparasitic Drugs Market was valued at USD 22.7 billion in 2023 and is estimated to grow at a CAGR of 5.7% between 2024 and 2032 to reach USD 37 billion by 2032. High market growth can be attributed to factors such as rising prevalence of parasitic infections, increasing global travel and migration, and increasing public awareness campaigns and educational programs.
 

For instance, according to the World Health Organization, in 2023, over 600 million people were estimated to be infected by Strongyloides stercoralis (helminths), with highest prevalence reported in sub-Saharan Africa, China, South America, and Asia. Such high prevalence of parasitic infections globally contributes to a growing disease burden. This rise in the number of infected individuals creates a greater demand for effective treatment options, thereby driving the antiparasitic drugs market.
 

Antiparasitic drugs are a class of medications specifically designed to treat infections caused by parasitic organisms. Parasites are living organisms that depend on other organisms, known as hosts, for their survival and reproduction. Parasites can include various types of organisms, such as protozoa, helminths (worms), and arthropods. Antiparasitic drugs act by different mechanisms, such as killing the parasite, inhibiting its growth and reproduction, or interfering with its ability to infect the host.
 

Antiparasitic Drugs Market Trends

• Surging government initiatives and increased funding has emerged as a pivotal driver propelling the antiparasitic drugs industry. Recognizing the profound impact of parasitic infections on public health, governments worldwide have intensified efforts to address these issues by allocating substantial resources towards research, development, and distribution of antiparasitic drugs.
   
• For instance, U.S. President’s Malaria Initiative (PMI), led by USAID, is a significant government initiative that contributes to market growth in the antiparasitic drugs sector.
   
• Further, financial support facilitates advancements in drug discovery services, encourages innovative treatment approaches, and enhances the accessibility of antiparasitic medications.
   
• Thus, with continuous efforts from governments and healthcare organizations, the antiparasitic drugs market is anticipated to witness continuous growth over the forecast years.
   

However, development of drug resistance to certain drugs leads to a decrease in the effectiveness of antiparasitic drugs. Parasites that have developed resistance are less susceptible to the drugs, rendering standard treatment regimens less effective. This can lead to persistent symptoms, increased morbidity, and a higher risk of complications. This might impede the market growth to a certain extent.
 

Antiparasitic Drugs Market Analysis

Based on drug type, the global antiparasitic drugs is segmented into anthelmintics, antiprotozoal, ectoparasiticides, and other drug types. The anthelminthics segment held the largest market share of 50.2% in 2023.
 

• Helminthic infections, caused by parasitic worms, are widespread in many parts of the world, especially in tropical and subtropical regions.
   
• For instance, according to the Pan American Health Organization, approximately 1.5 billion people are infected with soil-transmitted helminths worldwide, making this the most common infection in the world. Also, as per Centers for Disease Control and Prevention, ~ 807 to 1,121 million people are infected with Ascaris globally.
   
• Anthelmintics drugs are designed to target various types of helminths, including nematodes (roundworms), cestodes (tapeworms), and trematodes (flukes). This broad spectrum of activity makes anthelmintics versatile in treating different parasitic worm infections and thereby fosters the segmental growth.
   

Based on route of administration, the global antiparasitic drugs is classified into injectable, oral, and topical. The injectable segment held the largest market revenue of USD 11.7 billion in 2023.
 

• Injectable formulations often provide a faster onset of action compared to oral formulations. Additionally, some antiparasitic drugs have better bioavailability when administered through the injectable route, ensuring that a higher proportion of the drug reaches the systemic circulation.
   
• Further, injectable formulations are widely used in clinical trials and research studies to evaluate the safety and efficacy of new antiparasitic drugs. This contributes to the high use of injectable antiparasitic drugs, thereby contributing towards high segmental growth.
   

Based on End user, the global antiparasitic drugs is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to reach the largest market revenue of USD 14.7 billion by 2032.
 

• Hospital pharmacies maintain a diverse range of antiparasitic medications, ensuring comprehensive treatment options for various parasitic infections. Additionally, hospitals serve as the primary point of care for patients with severe or complicated parasitic conditions, further leading to increased patient footfall in these pharmacies.
   
• Moreover, these pharmacies along with their skilled staffs provide a controlled environment and center for the administration of drugs, ensuring accurate dosing, monitoring, and management of potential side effects. All these factors together boost the segmental growth.
   

In 2023, North America held a significant share of 36.8% in the global antiparasitic drugs market.
 

• High market growth can be attributed to increasing cases of parasitic infections in the region. For instance, according to the World Health Organization, in 2021, more than 723,000 cases of malaria were reported in North America. Furthermore, as per the report published by the Sepsis Organization, in 2021, toxoplasmosis and giardia infections are the two most common parasitic infections in North America.
   
• Further, North America, particularly the U.S., has one of the highest levels of healthcare spending globally. This substantial investment in healthcare infrastructure and services contributes to the prominence of the region in various pharmaceutical markets, including antiparasitic drugs.
   

Such aforementioned factors are expected to propel the antiparasitic drugs in the North American market.
 

Antiparasitic Drugs Market Share

The antiparasitic drugs industry is characterized by diverse players competing in the industry. Novartis AG, GlaxoSmithKline plc, Merck KGaA, and Zydus Group account for significant market share. These prominent players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion, research and development, product diversification, and regulatory compliance to maintain a competitive edge in the market.
 

Antiparasitic Drugs Market Companies

Foremost players operating in the antiparasitic drugs industry are as mentioned below:

• Bayer AG
• Cipla Inc.
• Dr. Reddy’s Laboratories Ltd
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd
• Ipca Laboratories Ltd.
• Mankind Pharma
• Merck KGaA
• Novartis AG
• Sanofi
• Zydus Group
   

Antiparasitic Drugs Industry News

• In July 2021, Dr. Reddy’s Laboratories Ltd, received the U.S. FDA approval to launch hydroxychloroquine sulfate tablets for the treatment of malaria. This helped the company to increase its product portfolio and generate higher sales.
   
• In September 2018, Cipla received the final approval for generic version of Impax Laboratories, Inc.’s Albenza (Albendazole tablets 200mg) from the U.S. FDA. This helped the company to expand its product offerings and cater to a larger customer base.
   

The global antiparasitic drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Anthelmintics
• Antiprotozoal
• Ectoparasiticides
• Other drug types

Market, By Route of Administration

• Injectable
• Oral
• Topical

Market, By End-user

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa